|
G |
Ache |
acetylcholinesterase |
multiple interactions |
ISO |
acetaldehyde oxime inhibits the reaction [tabun results in decreased activity of ACHE protein] |
CTD |
PMID:22960624 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
EXP ISO |
Aldicarb results in decreased activity of ACHE protein |
CTD |
PMID:8134223 PMID:14644616 PMID:16256972 PMID:21251949 PMID:23962483 PMID:27132127 PMID:33844597 More...
|
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
App |
amyloid beta precursor protein |
decreases response to substance |
ISO |
APP protein modified form results in decreased susceptibility to Aldicarb |
CTD |
PMID:34902447 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
EXP |
Aldicarb results in decreased activity of [CHRNA4 protein binds to CHRNB4 protein] |
CTD |
PMID:14644616 |
|
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
EXP |
Aldicarb results in decreased activity of [CHRNA4 protein binds to CHRNB4 protein] |
CTD |
PMID:14644616 |
|
NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Aldicarb inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:9126867 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Il2 |
interleukin 2 |
decreases response to substance |
ISO |
Aldicarb results in decreased susceptibility to IL2 protein |
CTD |
PMID:8349949 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions |
ISO |
Aldicarb promotes the reaction [[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with LDN 193189] results in increased expression of MAP2 mRNA] |
CTD |
PMID:32949729 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Nefh |
neurofilament heavy chain |
increases phosphorylation |
ISO |
Aldicarb results in increased phosphorylation of NEFH protein |
CTD |
PMID:16256972 |
|
NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351
|
|
G |
Nrxn1 |
neurexin 1 |
multiple interactions |
ISO |
NRXN1 protein affects the reaction [NLG-1 results in increased susceptibility to Aldicarb]; NRXN1 protein affects the reaction [NRX-1 results in decreased susceptibility to Aldicarb] |
CTD |
PMID:23638761 |
|
NCBI chr 6:3,177,788...4,323,848
Ensembl chr 6:3,177,897...4,322,710
|
|
G |
Pax6 |
paired box 6 |
multiple interactions |
ISO |
Aldicarb inhibits the reaction [[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with LDN 193189] results in increased expression of PAX6 mRNA] |
CTD |
PMID:32949729 |
|
NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Aldicarb inhibits the reaction [Progesterone results in increased activity of PGR protein] |
CTD |
PMID:9126867 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions |
ISO EXP |
[Calcium results in increased activity of PON1 protein] which results in decreased susceptibility to Aldicarb; [Egtazic Acid results in decreased activity of PON1 protein] which results in increased susceptibility to Aldicarb |
CTD |
PMID:27132127 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Vpreb1a |
V-set pre-B cell surrogate light chain 1A |
decreases expression |
ISO |
Aldicarb results in decreased expression of VPREB1 mRNA |
CTD |
PMID:25424538 |
|
NCBI chr11:84,126,969...84,127,846
Ensembl chr11:84,126,969...84,127,846
|
|